Levee Medical Marks First Patient Enrollment in ARID II Pivotal Trial

According to a recent LinkedIn post from Levee Medical, the University of Rochester Medical Center and Dr. Thomas Frye have enrolled their first patient in the ARID II IDE pivotal trial. The post indicates that this study is designed to evaluate the Voro® Urologic Scaffold and its impact on early and long-term continence following prostate surgery.

The LinkedIn post highlights this enrollment as a meaningful step in advancing post-prostatectomy care and improving patient outcomes. For investors, successful progression of the ARID II pivotal trial could be an important value inflection point, potentially supporting future regulatory pathways, strengthening clinical evidence, and enhancing Levee Medical’s positioning in the urologic devices market.